06/04/2025
Lamassu Biotech, the North Carolina-based biopharmaceutical company that opened a Cleveland office last year, has received a $2.7 million grant from the National Institutes of Health to help develop its therapy for dogs with acute pancreatitis.
The therapeutic, called RABI-767, also could potentially be used to treat humans, Lamassu Biotech said in a statement.